Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

<p>Multiplex immunohistochemical staining protocols.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Hansol Lee (15054787) (author)
Andere auteurs:	Angela L. Ferguson (15050051) (author), Camelia Quek (15049218) (author), Ismael A. Vergara (15054784) (author), Ines Pires daSilva (15056800) (author), Ruth Allen (15056803) (author), Tuba Nur Gide (15056806) (author), Jordan W. Conway (15056809) (author), Lambros T. Koufariotis (15056812) (author), Nicholas K. Hayward (14956488) (author), Nicola Waddell (12694196) (author), Matteo S. Carlino (15056815) (author), Alexander M. Menzies (11420816) (author), Robyn P.M. Saw (15056818) (author), Elena Shklovskaya (15056821) (author), Helen Rizos (15008946) (author), Serigne Lo (15056824) (author), Richard A. Scolyer (10778711) (author), Georgina V. Long (11420813) (author), Umaimainthan Palendira (15050084) (author), James S. Wilmott (15008931) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers Prognostic biomarkers Immunology Immune responses to cancer Innate immunity Tumor-associated macrophages Immunotherapy Biomarkers for immunotherapy Checkpoint blockade Combination immunotherapy Skin Cancers Melanoma
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
door: Hansol Lee (15054787)
Gepubliceerd in: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
door: Hansol Lee (15054787)
Gepubliceerd in: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
door: Hansol Lee (15054787)
Gepubliceerd in: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
door: Renumathy Dhanasekaran (14962092)
Gepubliceerd in: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
door: Hiroshi Kagamu (14961732)
Gepubliceerd in: (2025)

Supplementary File 1 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
door: Huaibin Ge (15047462)
Gepubliceerd in: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
door: Andrew O. Yam (15293045)
Gepubliceerd in: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
door: Daniel S. Green (15047598)
Gepubliceerd in: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
door: Carlotta Antoniotti (15352506)
Gepubliceerd in: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
door: Carlotta Antoniotti (15352506)
Gepubliceerd in: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
door: Carlotta Antoniotti (15352506)
Gepubliceerd in: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
door: Caroline Robert (15032672)
Gepubliceerd in: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
door: Arianna Draghi (15126339)
Gepubliceerd in: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
door: Arianna Draghi (15126339)
Gepubliceerd in: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
door: Arianna Draghi (15126339)
Gepubliceerd in: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
door: Jonathan M.J. Derry (16648337)
Gepubliceerd in: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
door: Jonathan M.J. Derry (16648337)
Gepubliceerd in: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
door: Jonathan M.J. Derry (16648337)
Gepubliceerd in: (2025)

Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
door: Jonathan M.J. Derry (16648337)
Gepubliceerd in: (2025)

Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
door: Jonathan M.J. Derry (16648337)
Gepubliceerd in: (2025)

Supplementary Table S6A from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
door: Jonathan M.J. Derry (16648337)
Gepubliceerd in: (2025)

Supplementary Table S6B from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
door: Jonathan M.J. Derry (16648337)
Gepubliceerd in: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
door: Jian Wang (15048011)
Gepubliceerd in: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
door: Sahar Mafi (16721657)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_fb5rfrtggmruafoj62kjbd24fo